Az akut légzési elégtelenség kezelésének gyógyszerköltség-elemzése.

Translated title of the contribution: Analysis of costs of drug therapy in patients with acute respiratory insufficiency

L. Bogár, A. Safrankó, J. A. Horváth, M. Tekeres

Research output: Contribution to journalArticle

Abstract

In a retrospective study, the authors analysed the clinical data of 38 patients who were admitted to a surgical intensive care unit (SICU) for mechanical ventilation lasted for at least 72 hours. The APACHE III score was calculated on the basis of clinical data documented during the first 24 hour of the treatment and the cost of drug administrations per patients per day was also determined by analysing all the drugs prescribed on the first 5 days of intensive care. The patients admitted to SICU with polytrauma or with abdominal septic focus required significantly higher cost of drug treatment than the patients after cardiopulmonary resuscitation or with bronchial asthma or pneumonia. The APACHE III score of the patients died at the SICU was significantly higher compared to the survivors who needed more expensive drug therapy than the non-survivors required. Antibiotic treatment, blood transfusions, and human plasma proteins caused the highest drug expenditure. There was no significant correlation between the APACHE III score and the cost of drug treatment.

Translated title of the contributionAnalysis of costs of drug therapy in patients with acute respiratory insufficiency
Original languageHungarian
Pages (from-to)129-133
Number of pages5
JournalOrvosi hetilap
Volume137
Issue number3
Publication statusPublished - Jan 21 1996

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Analysis of costs of drug therapy in patients with acute respiratory insufficiency'. Together they form a unique fingerprint.

  • Cite this

    Bogár, L., Safrankó, A., Horváth, J. A., & Tekeres, M. (1996). Az akut légzési elégtelenség kezelésének gyógyszerköltség-elemzése. Orvosi hetilap, 137(3), 129-133.